

Applicants: Graham P. Allaway, et al.  
Serial No.: 09/460,216  
Filed: December 13, 1999  
Page 2

such that fusion of HIV-1 or an HIV-1 infected cell to the CD4+ cells is inhibited, so as to thereby inhibit HIV-1 infection of the CD4+ cells, provided that the nonchemokine peptidyl agent is not a bicyclam or a derivative thereof.--

- 62. (Amended) The method of claim 61, wherein the non-chemokine [peptidyl] agent is an oligopeptide.--
- 63. (Amended) The method of claim 61, wherein the non-chemokine [peptidyl] agent is a polypeptide.--
- 64. (Amended) The method of claim 63, wherein the non-chemokine [peptidyl] agent is an antibody or portion of an antibody.--

#### Remarks

Claims 61-64 were pending in the subject application. Applicants have hereinabove amended claims 61-64. Support for these amendments may be found inter alia in the specification on page 13, lines 1-6. Accordingly, claims 61-64 do not involve any issue of new matter such that entry of this amendment is respectfully requested.

The February 24, 2000 Notice states that the nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): this application does not contain as a separate part of the disclosure on paper copy a "sequence listing" as required by 37 CFR 1.82(c); and a copy of the "sequence listing" in computer readable form has not been submitted as required by 37 CFR 1.82(e).

The Notice also states that applicant must provide: an initial